Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 2/20 | 0.80 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | PDE4A | P27815 | 1/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.65 |
| ▸ | TTPA | P49638 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3139787 | 1.00 | GSTO1 (0.80) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL16075621 | 1.00 | GSTO1 (0.80) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL12939323 | 1.00 | GSTO1 (0.80) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL12535813 | 0.97 | GSTO1 (0.75) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL19725725 | 0.96 | GSTO1 (0.74) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL16075620 | 0.95 | GSTO1 (0.84) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL19194502 | 0.95 | GSTO1 (0.75) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL29642083 | 0.95 | GSTO1 (0.75) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL4619077 | 0.93 | GSTO1 (0.93) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL17749237 | 0.93 | GSTO1 (0.93) | GSTO1PTPN1MEN1KMT2APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108543-A1 | Self-Emulsifying Systems For Cannabinoids | FERTIN PHARMA A/S (DK) | 2026-04-23 | — | — | US | claimed |
| EP-4724045-A1 | SOLID ORAL DOSAGE FORMS OF ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260083757-A1 | Dosage Forms For Delivery Of Self-Emulsifying Drug Delivery Systems | FERTIN PHARMA A/S (DK) | 2026-03-26 | — | — | US | claimed |
| US-20260083710-A1 | TREATMENT OF MIGRAINE | ALLERGAN PHARMACEUTICALS INT LTD (IE) | 2026-03-26 | — | — | US | claimed |
| US-20260083756-A1 | Capsules With Self-Emulsifying Drug Delivery Systems | FERTIN PHARMA A/S (DK) | 2026-03-26 | — | — | US | claimed |
| CN-121586574-A | Solid dispersion of inhibitors of myeloid kinase group and pharmaceutical compositions comprising the same | 韩美药品株式会社 | 2026-02-27 | — | — | CN | claimed |
| EP-4698205-A1 | PHARMACEUTICAL FORMULATIONS FOR LONGEVITY IN MAMMALS | Cellular Longevity, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| EP-4683621-A1 | SELF-EMULSIFYING SYSTEMS FOR CANNABINOIDS | Fertin Pharma A/S (DK) | 2026-01-28 | — | — | EP | claimed |
| US-12533367-B2 | Self-emulsifying systems for cannabinoids | FERTIN PHARMA A/S (DK) | 2026-01-27 | — | — | US | claimed |
| CN-113201131-B | Method for preparing d-alpha-tocopherol polyethylene glycol succinate by using leftovers | 山东新元素生物科技有限公司 | 2022-08-23 | — | — | CN | claimed |
| WO-2022160065-A1 | FORMULATIONS INCLUDING DIHYDROHONOKIOL | BETTERLIFE PHARMA INC. (CA) | 2022-08-04 | — | — | WO | claimed |
| CN-114786670-A | A pharmaceutical oral dosage form | 奎利恩特有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-20220211643-A1 | ADRENALINE PHARMACEUTICAL SOLUTION FOR AN INJECTION DEVICE | CROSSJECT (FR) | 2022-07-07 | — | — | US | claimed |
| EP-4021411-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF MELATONIN FOR ORAL AND PARENTERAL ADMINISTRATION | Redasani, Vijayendrakumar Virendrakumarji (IN) | 2022-07-06 | — | — | EP | claimed |
| CN-110337288-B | Package containing nano-crystalline herbal ingredients and method for preparing herbal decoction | 纳米及先进材料研发院有限公司 | 2022-06-21 | — | — | CN | claimed |
| EP-4007590-A1 | FORMULATIONS INCLUDING DIHYDROHONOKIOL | Kirkland, Justin (US) | 2022-06-08 | — | — | EP | claimed |
| WO-2022101826-A1 | PHARMACEUTICAL FORMULATION | ASTRAZENECA UK LIMITED (GB) | 2022-05-19 | — | — | WO | claimed |
| WO-2022094054-A1 | NOVEL FUNGAL COMPOUND FORMULATIONS AND THEIR THERAPEUTIC METHODS OF USE | MYDECINE INNOVATIONS GROUP INC. (US) | 2022-05-05 | — | — | WO | claimed |
| CN-110496251-B | Cationic nano-drug, preparation method thereof and drug-loaded implant medical device | 上海微创医疗器械（集团）有限公司 | 2022-04-01 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533367-B2 | Self-emulsifying systems for cannabinoids | CNR1, CNR2, SI | GSTO1 3044/4885PTPN1 2624/4885MEN1 1748/4885 |
| US-20260108543-A1 | Self-Emulsifying Systems For Cannabinoids | CNR1, CNR2, SGMS1 | GSTO1 1267/4885PTPN1 2219/4885MEN1 2866/4885 |
| US-20260083756-A1 | Capsules With Self-Emulsifying Drug Delivery Systems | CNR2, CNR1, SI | GSTO1 1569/4885PTPN1 3579/4885MEN1 3791/4885 |
| US-20260083757-A1 | Dosage Forms For Delivery Of Self-Emulsifying Drug Delivery Systems | CNR1, SI, CNR2 | GSTO1 3150/4885PTPN1 2974/4885MEN1 2869/4885 |
| US-20260083710-A1 | TREATMENT OF MIGRAINE | GABARAP, ABCB1, GABARAPL1 | GSTO1 1646/4885PTPN1 3780/4885MEN1 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.